Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: November 2014

Chapter 8 - Congenital heart disease: Arrhythmias, cardiopulmonary bypass, and “grown-ups”

Further reading

1. NavaratnamM, DubinA. Pediatric pacemakers and ICDs: how to optimize perioperative care. Paediatr Anaesth 2011; 21(5); 512–21.
2. FortescueEB, BerulC, CecchinFet al. Patient, procedural and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm 2004; 1: 150–9.
3. CohenMI, BushDM, VetterVLet al. Permanent epicardial pacing in pediatric patients: seventeen years of experience and 1200 outpatient visits. Circulation 2001; 103: 2585–90.
4. MohamadyH, SalehM, AhmedH. Disasters in pediatric cardiac catheterization laboratory. Ain Shams J Anesthesiol 2012; 5 (2): 121–5.
5. ChunT. Pacemakers and defibrillator therapy in pediatrics and congenital heart disease. Future Cardiol 2008; 4: 469–79.
6. ShahMJ. Implantable cardioverter defibrillator-related complications in the pediatric population. Pacing Clin Electrophysiol 2009; 32: S71–S74.
7. MathonyU, SchmidtH, GrogerCet al. Optimal maximum tracking rate of dual chamber pacemakers required by children and young adults for a maximal cardiorespiratory performance. Pacing Clin Electrophysiol 2005; 28: 378–83.
8. BernsteinAD, DaubertJ-C, FletcherRDet al. Naspe Position Statement. The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing. Pacing Clin Electrophysiol 2002; 25: 260–4.
9. StoneME, ApinisA. Current perioperative management of the patient with a cardiac rhythm management device. Semin Cardiothorac Vasc Anesth 2009; 13: 31–43.
10. KnightBP, GershBJ, CarlsonMDet al. Role of permanent pacing to prevent atrial fibrillation. Circulation 2005; 111: 240–3.
11. EpsteinAE, Di MarcoJP, ElenborgenKAet al. ACC/AHA/HRS2008 guide- lines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: E350–E408.
12. AndrewsRE, TullohRM. Interventional cardiac catheterization in congenital heart disease. Arch Dis Child 2004; 89 (12): 1168–73.
13. BennetD, Marcus R, Stokes M. Incidents and complications during pediatric cardiac catheterization. Paediatr Anaesth 2005; 15(12): 1083–8.
14. SchroederVAet al. Surgical emergencies during pediatric interventional catheterization. J Pediatr 2002 140(5): 570–5.
15. PhodesJFet al. Impact of how body weight on frequency of pediatric cardiac catheterization complications. Am J Cardiol 2000 86(11): 1275–8.
16. WalshE, AlexanderM, CecchinF. Electrocardiography and introduction to electrophysiologic techniques. In KeaneJ, LockJ, FylerD, eds. Nada’s Pediatric Cardiology, 2nd edition. Philadelphia, PA: Elsevier. 2006. pp.145–72.
17. TrirediK, DubinA, PerryS, et al.Out of operating room procedures: pediatric catherizarion and electrophysiology. Anesthesiologist’s Manual of Surgical Procedures, 4th edition. Philadelphia, PA: Lippincott Williams and Wilkins. 2009. Pp. 1493–5.
18. LakeC, BookerPet al. Pediatric electrocardiography and cardiac electrophysiology. Pediatric Cardiac Anesthesiology 2005; 138–51.
19. DubinAM, JanousekJ, RheeEet al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol 2005; 46: 2277–83.
20. StephensonEA, BatraAS, KnilansTKet al. A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population. J Cardiovasc Electrophysiol 2006; 17: 41–6.
21. RoznerMA. The patient with a cardiac pacemaker or implanted defibrillator and management during anesthesia. Anesthesia and medical disease. Current Opin Anaesthesiol 2007; 20: 261–8.
22. BerulCI, VanHareGF, KerteszMJet al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008; 51: 1685–91.
23. SilkaMJ, KronJ, DunniganAet al. Sudden cardiac death and the use of implantable cardioverter defibrillators in pediatric patients. Circulation 1993; 87: 800–7.
24. AlexanderME, CecchinF, WalshEPet al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol 2004; 15: 72–6.
25. ZaidanJR, AtleeJL, BelottPet al. Practice advisory for the perioperative management of patients with cardiac rhythm management devices: pacemakers and implantable cardioverter defibrillators: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices. Anesthesiology 2005; 103: 186–98.
26. MychaskiwG, EichhornJH. Interaction of an implanted pacemaker with a transesophageal atrial pacemaker: report of a case. J Clin Anesth 1999; 11: 669–71.
27. PurdayJP, ToweyRM. Apparent pacemaker failure caused by activation of ventricular threshold test by a magnetic instrument during general anaesthesia. Br J Anaesth 1992; 69: 645–6.
28. KellowNH. Pacemaker failure during transurethral resection of the prostate. Anesthesia 1993; 48: 136–8.
29. JoshiGP. Perioperative management of outpatients with implantable cardioverter defibrillators. Curr Opin Anaesthesiol 2009; 22: 701–4.
30. RoznerMA. Review of electrical interference in implanted cardiac devices. Pacing Clin Electrophysiol 2003; 26: 923–5.
31. DohrmannML, GoldschlagerNF. Myocardial stimulation threshold in patients with cardiac pacemakers: effect of physiologic variables, pharmacologic agents, and lead electrodes. Cardiol Clin 1985; 3: 527–37.
32. SchureAV. Cardiopulmonary bypass in infants and children: what’s new?South African Journal of Anesthesia and Analgesia 2010; 16 (1): 25–7.
33. HsiaTY, GruberPJ. Factors influencing neurologic outcome after neonatal cardiopulmonary bypass: what we can and cannot control. Ann Thoracic Surg 2006; 81: S2381–S2388.
34. ShenI, GiacomuzziC, UngerleiderRM. Current strategies for optimizing the use of cardiopulmonary bypass in neonates and infants. Ann Thoracic Surg 2003; 75: S729–S734.
35. DavisPJ, CladisFP, MotoyamaEK. Smith’s Anesthesia for Infants and Children, 8th edition. Elsevier, 2011.
36. GravleeGP, DavidRF, StammersAH, UngerliderRM. Cardiopulmonary Bypass Principles and Practice, 3rd edition. Lippincott, Williams and Wilkins, 2008.
37. LakeCL, BookerPD. Pediatric Cardiac Anesthesia, 4th edition. Lippincott, Williams and Wilkins, 2005.
38. HickeyE, KaramlouT, YouJ, UngerleiderRM. Effects of miniaturization in reducing inflammatory response to infant cardiopulmonary bypass by elimination of allogeneic blood products. Ann Thorac Surg 2006; 81: S2367–S2372.
39. LovellA. Anaesthetic implications of frown-up congenital heart disease. Br J Anaesth 2004; 93(1): 129–39.
40. CannessonM, CollangeV, LehotJJ. Anesthesia in adult patients with congenital heart disease. Curr Opin Anaesthesiol 2009; 22: 88–94.
41. PerloffJK, WarnesCA. Challenges posed by adults with repaired congenital heart disease. Circulation 2001: 103: 2637–43.
42. RhodesJF, HijaziZM, SommerRJ. Pathophysiology of congenital heart disease in the adult, Part II: Simple obstructive lesions. Circulation 2008; 117: 1228–37.
43. SommerRJ, HijaziZM, SommerRJ. Pathophysiology of congenital heart disease in the adult, Part I: Shunt lesions. Circulation 2008; 117: 1090–9.
44. DeanfieldJ, ThaulowE, WarnesCet al. Management of grown up congenital heart disease. Task force of European Society of Cardiology 2003. Eur Heart J 2003 l; 24: 1035–84.
45. WarnesCA, LiberthsonR, DanielsonGKet al. Task force: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 2001; 37: 1170–8.
46. MarelliAJ, MackieAS, Ionescu-lttuRet al. Congenital heart disease in the general population; changing prevalence and age distribution. Circulation 2007; 115: 163–2.
47. GigliaTM, HumplT. Preoperative pulmonary hemodynamics and assessment of operability: is there a pulmonary vascular resistance that precludes cardiac operation?Pediatr Crit Care Med 2010; 11(2 Suppl): S57–S69.
48. KrasuskiRA, DevendraGP, HartSAet al. Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension. J Card Fail 2011; 17(4): 265–71.
49. MulderBJ. Changing demographics of pulmonary arterial hypertension in congenital heart disease. Eur Respir Rev 2010; 19(118): 308–13.
50. ShapiroS, TraigerGL, TurnerMet al. Gender differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Chest 2012; 141(2): 363–73.
51. KlitznerTS, LeeM, RodriguezS, ChangRK. Sex-related disparity in surgical mortality among pediatric patients. Congenit Heart Dis 2006; 1(3): 77–88.
52. WarnesCA, WilliamsRG, BashoreTMet al. ACC/AHA 2008 Guidelines for the management of adults with congenital heart disease: executive summary. Circulation 2008; 118: 2395–451.